Has Mario Leitao, MD received payments from drug or device companies?

Yes. Drug and device makers reported $116,022 in general payments to Mario Leitao, MD across 202 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mario Leitao, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mario Leitao, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mario Leitao, MD

Gynecologic Oncology · New York, NYNPI 1225068372

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (37.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Intuitive Surgical at 56.6% of the total. Reporting peaked in 2019 at $40,610 and has fallen 67.5% since, to $13,193 in 2025. Among gynecologic oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$116,022in general payments, 2019–2025

Across 202 payments — averaging $574.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intuitive Surgical$66K
Johnson & Johnson$22K
Covidien LP$12K
Medtronic$8K
Merck$4K
Medical Device Business Services, Inc.$2K
plus $2K from 14 others

$91,180in research payments, 2019–2025

Across 4 payments — averaging $22,795 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

KCI USA, Inc.$90K
Takeda Pharmaceuticals U.S.A., Inc.$930

What the payments were for

Consulting fees$22,00019%
Speaking & faculty fees$43,34837%
Travel & lodging$22,23519%
Food & beverage$9,4388%
Education$19,00016%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intuitive Surgical	116	$65,696
Johnson & Johnson(2 entities)	14	$22,114
Covidien LP	12	$12,003
Medtronic	25	$8,402
Merck	1	$4,270
Medical Device Business Services, Inc.	13	$1,512
AstraZeneca	4	$457
Biom'up France SAS	2	$278
Baxter Healthcare	2	$247
Dilon Technologies, Inc.	1	$165
Coopersurgical, Inc.	1	$125
AbbVie	1	$125
Immunogen, Inc.	1	$124
Biom'up SA	1	$116
KCI USA, Inc.	1	$115
Integra Lifesciences Corporation	1	$98
Genmab U.S., Inc.	1	$62
Clovis Oncology, Inc.	2	$45
Davol Inc.	2	$36
R-pharm US LLC	1	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,022 in reported general payments places this provider in the 95th percentile of 154 gynecologic oncology providers in New York.

See all gynecologic oncology providers in New York →

Medicare billing

Part B allowed, 2024

$112,390

Medicare patients

209

Services billed

486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in New York

Bhavana PothuriNew York$366K
Konstantin ZakashanskyNew York$93K
Evelyn CantilloNew York$79K
Farr NezhatNew York$41K
Kristen ZeligsNew York$38K
Nimesh NagarshethNew York$33K
Jeff LinNew York$30K
Valentin KolevNew York$23K
Jason WrightNew York$19K
Kevin HolcombNew York$13K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →